KSPHF (Kissei Pharmaceutical Co) Cyclically Adjusted PS Ratio: (As of Sep. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KSPHF Kissei Pharmaceutical Co Ltd KSPHF
77 GF Score
Price $25.77
GF Value $30.13
! 1 Warning Sign
View Full Analysis

What is Kissei Pharmaceutical Co Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Kissei Pharmaceutical Co  (OTCPK:KSPHF) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Kissei Pharmaceutical Co Cyclically Adjusted PS Ratio Related Terms


Kissei Pharmaceutical Co Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Kissei Pharmaceutical Co's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kissei Pharmaceutical Co Cyclically Adjusted PS Ratio Chart

Kissei Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.54 1.38 1.68 1.70 1.79

Kissei Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.91 2.12 1.87 1.78 1.78

KSPHF vs ZTS: Cyclically Adjusted PS Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Kissei Pharmaceutical Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kissei Pharmaceutical Co Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kissei Pharmaceutical Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Kissei Pharmaceutical Co's Cyclically Adjusted PS Ratio falls into.


KSPHF
77GF Score
Kissei Pharmaceutical Co Ltd KSPHF
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kissei Pharmaceutical Co Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Kissei Pharmaceutical Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Kissei Pharmaceutical Co's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=3.541/113.6000*113.6000
=3.541

Current CPI (Jun. 2026) = 113.6000.

Kissei Pharmaceutical Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 3.330 98.000 3.860
201612 3.537 98.400 4.083
201703 3.116 98.100 3.608
201706 3.510 98.500 4.048
201709 3.308 98.800 3.804
201712 3.702 99.400 4.231
201803 3.367 99.200 3.856
201806 3.503 99.200 4.012
201809 3.422 99.900 3.891
201812 3.718 99.700 4.236
201903 3.312 99.700 3.774
201906 3.137 99.800 3.571
201909 3.081 100.100 3.497
201912 3.348 100.500 3.784
202003 2.884 100.300 3.266
202006 3.197 99.900 3.635
202009 3.271 99.900 3.720
202012 4.079 99.300 4.666
202103 3.414 99.900 3.882
202106 3.296 99.500 3.763
202109 3.103 100.100 3.521
202112 3.374 100.100 3.829
202203 2.852 101.100 3.205
202206 2.725 101.800 3.041
202209 2.600 103.100 2.865
202212 2.877 104.100 3.140
202303 2.597 104.400 2.826
202306 3.054 105.200 3.298
202309 2.667 106.200 2.853
202312 3.141 106.800 3.341
202403 2.697 107.200 2.858
202406 3.074 108.200 3.227
202409 3.229 108.900 3.368
202412 3.505 110.700 3.597
202503 3.474 111.100 3.552
202506 3.664 111.700 3.726
202509 3.868 112.000 3.923
202512 4.197 113.000 4.219
202603 3.809 112.700 3.839
202606 3.541 113.600 3.541

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Kissei Pharmaceutical Co (KSPHF) Overvalued in 2026?

Based on GuruFocus' analysis, Kissei Pharmaceutical Co stock appears to be undervalued. The current stock price of $25.77 is trading 14.5% below its estimated GF Value™ of $30.13.

Key valuation signals for KSPHF:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: $30.13 vs. price of $25.77 (14.5% below fair value)
  • GF Score™: 77/100 with 1 warning sign

No single metric tells the full story. See the KSPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Kissei Pharmaceutical Co Business Description

Other Exchanges 4547:Japan
Address 19-48, Yoshino, Matsumoto City, Nagano, JPN, 399-8710
Kissei Pharmaceutical Co Ltd is a specialty and generic drug manufacturing company. Pharmaceuticals is the company's reportable segment. The company's operations span across the globe, while the vast majority of revenue is generated in Japan, followed by Europe. Kissei operates a variety of subsidiaries. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
77GF Score

Get the complete analysis for KSPHF

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$25.77
Price
$30.13
GF Value